Predisposing and Overall Effects of Reproductive Hormones on Breast Cancer: A Review
- PMID: 37900385
- PMCID: PMC10600026
- DOI: 10.7759/cureus.45956
Predisposing and Overall Effects of Reproductive Hormones on Breast Cancer: A Review
Abstract
Cancer, the second leading cause of mortality worldwide, has been the subject of extensive and quickly changing scientific study and practice. Cancer remains a mystery despite the enormous effort put into understanding the genesis of cancerous cells, the development of malignant tissues, and the process by which they propagate and recur. Cells from humans that have been recruited by cancer and, to some extent, changed into pathogenic organisms or the foundation of tumors serve as agents of destruction. Understanding cancers leads to challenging philosophical issues since they undermine and use multicellular organization processes. Cancer metastasizing cells adopt new phenotypes while discarding previous behaviors. The absence of comprehensive knowledge of this has hampered the development of therapeutics for metastatic illness. For systems-level experimental and computational metastasis modeling, integrating these complex and interconnected features continues to be a problem because metastasis has typically been studied in separate physiological compartments. Lung, breast, and prostate cancers accounted for the bulk of the 18 million new cases of cancer that were diagnosed in 2018. The most frequent cancer in women is breast cancer. Animal experimentation plays a significant role in primary and translational breast cancer research. In theory, such breast cancer models should be comparable to breast cancer in humans in terms of tumor etiology, biological behavior, pathology, and treatment response.
Keywords: breast cancer; hypothalamic and pituitary hormones; ovarian hormones; placental hormones; uterine hormones.
Copyright © 2023, Sarda et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
-
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.Oncologist. 1996;1(5):326-330. Oncologist. 1996. PMID: 10388011
-
Hypophysectomy in the treatment of disseminated carcinoma of the breast and prostate gland.South Med J. 1976 May;69(5):579-83. doi: 10.1097/00007611-197605000-00029. South Med J. 1976. PMID: 1273614
-
From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.Adv Anat Pathol. 2007 May;14(3):149-77. doi: 10.1097/PAP.0b013e3180504abf. Adv Anat Pathol. 2007. PMID: 17452813 Review.
-
Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020.BMC Womens Health. 2022 Dec 7;22(1):504. doi: 10.1186/s12905-022-02104-2. BMC Womens Health. 2022. PMID: 36476597 Free PMC article.
References
-
- Epidemiology of breast cancer in women. Coughlin SS. Adv Exp Med Biol. 2019;1152:9–29. - PubMed
-
- [Hormone and breast cancer] Gompel A. Presse Med. 2019;48:1085–1091. - PubMed
-
- Placental supernatants' enhancement of the metastatic potential of breast cancer cells: is estrogen receptor (ERα) essential for this phenomenon? Bar M, Komemi O, Pomeranz M, Fishman A, Drucker L, Lishner M, Tartakover Matalon S. Arch Gynecol Obstet. 2019;300:981–991. - PubMed
Publication types
LinkOut - more resources
Full Text Sources